Dual roles of RNF2 in melanoma progression

Cancer Discovery

Volumn 5, Issue 12, 2015, Pages 1314-1327

  Rai, Kunal ^a   Akdemir, Kadir C ^a   Kwong, Lawrence N ^a   Fiziev, Petko ^b,c   Wu, Chang Jiun ^a   Keung, Emily Z ^a,d   Sharma, Sneha ^a   Samant, Neha S ^a   Williams, Maura ^a   Axelrad, Jacob B ^a   Shah, Amiksha ^a   Yang, Dong ^a   Grimm, Elizabeth A ^a   Barton, Michelle C ^a   Milton, Denai R ^a   Heffernan, Timothy P ^a   Horner, James W ^a   Ekmekcioglu, Suhendan ^a   Lazar, Alexander J ^a   Ernst, Jason ^b,c   Chin, Lynda ^a,e   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D2; E1A ASSOCIATED P300 PROTEIN; RING FINGER PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; BMI1 PROTEIN; CCND2 PROTEIN, HUMAN; HISTONE DEMETHYLASE; LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN; LTBP2 PROTEIN, HUMAN; NUCLEAR PROTEIN; RNF2 PROTEIN, HUMAN; UTX PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; GAIN OF FUNCTION MUTATION; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; LOSS OF FUNCTION MUTATION; LYMPHOMA; MELANOMA; METASTASIS; MOUSE; NEXT GENERATION SEQUENCING; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN ISOLATION; RNA ISOLATION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; ANIMAL; CATALYSIS; CELL TRANSFORMATION; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; ONCOGENE; PATHOLOGY; PHOSPHORYLATION; PROGNOSIS; PROMOTER REGION;

ANIMALS; CATALYSIS; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN D2; DISEASE PROGRESSION; E1A-ASSOCIATED P300 PROTEIN; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEMETHYLASES; HUMANS; LATENT TGF-BETA BINDING PROTEINS; MAP KINASE SIGNALING SYSTEM; MELANOMA; MICE; NEOPLASM METASTASIS; NUCLEAR PROTEINS; ONCOGENES; PHOSPHORYLATION; POLYCOMB REPRESSIVE COMPLEX 1; PROGNOSIS; PROMOTER REGIONS, GENETIC; TRANSFORMING GROWTH FACTOR BETA;

EID: 84960087431     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-15-0493     Document Type: Article

References (29)

1. Chi P, Allis CD, Wang GG. Covalent histone modifications–miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer 2010; 10: 457-69
2. Leong SP, Gershenwald JE, Soong SJ, Schadendorf D, Tarhini AA, Agarwala S, et al. Cutaneous melanoma: a model to study cancer metastasis. J Surg Oncol 2011; 103: 538-49
3. Scott KL, Nogueira C, Heffernan TP, van Doorn R, Dhakal S, Hanna JA, et al. Proinvasion metastasis drivers in early-stage melanoma are oncogenes. Cancer Cell 2011; 20: 92-103
4. Tyler JK, Adams CR, Chen SR, Kobayashi R, Kamakaka RT, Kadonaga JT. The RCAF complex mediates chromatin assembly during DNA replication and repair. Nature 1999; 402: 555-60
5. Thomas JO, Stott K. H1 and HMGB1: modulators of chromatin structure. Biochem Soc Trans 2012; 40: 341-6
6. Vidal M. Role of polycomb proteins Ring1A and Ring1B in the epigenetic regulation of gene expression. Int J Dev Biol 2009; 53: 355-70
7. Conaway RC, Conaway JW. The INO80 chromatin remodeling complex in transcription, replication and repair. Trends Biochem Sci 2009; 34: 71-7
8. de Napoles M, Mermoud JE, Wakao R, Tang YA, Endoh M, Appanah R, et al. Polycomb group proteins Ring1A/B link ubiquitylation of histone H2A to heritable gene silencing and X inactivation. Dev Cell 2004; 7: 663-76
9. Martinez-Romero C, Rooman I, Skoudy A, Guerra C, Molero X, Gonzalez A, et al. The epigenetic regulators Bmi1 and Ring1B are differentially regulated in pancreatitis and pancreatic ductal adenocarcinoma. J Pathol 2009; 219: 205-13
10. Sanchez-Beato M, Sanchez E, Gonzalez-Carrero J, Morente M, Diez A, Sanchez-Verde L, et al. Variability in the expression of polycomb proteins in different normal and tumoral tissues. A pilot study using tissue microarrays. Mod Pathol 2006; 19: 684-94
11. Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005; 436: 117-22
12. Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 2009; 9: 274-84
13. Talantov D, Mazumder A, Yu JX, Briggs T, Jiang Y, Backus J, et al. Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin Cancer Res 2005; 11: 7234-42
14. McDonald OG, Wu H, Timp W, Doi A, Feinberg AP. Genome-scale epigenetic reprogramming during epithelial-to-mesenchymal transition. Nat Struct Mol Biol 2011; 18: 867–74
15. Ben-Saadon R, Zaaroor D, Ziv T, Ciechanover A. The polycomb protein Ring1B generates self atypical mixed ubiquitin chains required for its in vitro histone H2A ligase activity. Mol Cell 2006; 24: 701-11
16. Wang H, Wang L, Erdjument-Bromage H, Vidal M, Tempst P, Jones RS, et al. Role of histone H2A ubiquitination in Polycomb silencing. Nature 2004; 431: 873-8
17. Kwong LN, Boland GM, Frederick DT, Helms TL, Akid AT, Miller JP, et al. Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma. J Clin Invest 2015; 125: 1459-70
18. Meulmeester E, Ten Dijke P. The dynamic roles of TGF-beta in cancer. J Pathol 2011; 223: 205-18
19. Bueno L, de Alwis DP, Pitou C, Yingling J, Lahn M, Glatt S, et al. Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice. Eur J Cancer 2008; 44: 142-50
20. Todorovic V, Rifkin DB. LTBPs, more than just an escort service. J Cell Biochem 2012; 113: 410-8
21. Hyytiainen M, Penttinen C, Keski-Oja J. Latent TGF-beta binding proteins: extracellular matrix association and roles in TGF-beta activation. Crit Rev Clin Lab Sci 2004; 41: 233-64
22. Vehvilainen P, Hyytiainen M, Keski-Oja J. Latent transforming growth factor-beta-binding protein 2 is an adhesion protein for melanoma cells. J Biol Chem 2003; 278: 24705-13
23. Ernst J, Kellis M. ChromHMM: automating chromatin-state discovery and characterization. Nat Methods 2012; 9: 215-6
24. Bernstein BE, Mikkelsen TS, Xie X, Kamal M, Huebert DJ, Cuff J, et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 2006; 125: 315-26
25. Illingworth RS, Botting CH, Grimes GR, Bickmore WA, Eskeland R. PRC1 and PRC2 are not required for targeting of H2A.Z to developmental genes in embryonic stem cells. PloS One 2012; 7: e34848
26. Rao PS, Satelli A, Zhang S, Srivastava SK, Srivenugopal KS, Rao US. RNF2 is the target for phosphorylation by the p38 MAPK and ERK signaling pathways. Proteomics 2009; 9: 2776-87
27. Eskeland R, Leeb M, Grimes GR, Kress C, Boyle S, Sproul D, et al. Ring1B compacts chromatin structure and represses gene expression independent of histone ubiquitination. Mol Cell 2010; 38: 452-64
28. Qin Y, Ekmekcioglu S, Liu P, Duncan LM, Lizee G, Poindexter N, et al. Constitutive aberrant endogenous interleukin-1 facilitates inflammation and growth in human melanoma. Mol Cancer Res 2011; 9: 1537-50
29. Garber M, Yosef N, Goren A, Raychowdhury R, Thielke A, Guttman M, et al. A high-throughput chromatin immunoprecipitation approach reveals principles of dynamic gene regulation in mammals. Mol Cell 2012; 47: 810-22.